Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Accord-UK Ltd (Trading style: Accord), Whiddon Valley, Barnstaple, Devon, EX32 8NS
Delmosart 18mg Prolonged-release Tablets.
| Pharmaceutical Form |
|---|
|
Prolonged-release tablet. 18 mg Tablet: Capsule-shaped, biconvex, yellow tablet, 6.6 mm x 11.9 mm, with "2392" printed on one side in black ink. |
Each prolonged-release tablet contains 18 mg of methylphenidate hydrochloride equivalent to 15.6 mg of methylphenidate.
Excipient with known effect: contains 183.8 mg of lactose (as monohydrate).
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Methylphenidate is a CNS stimulant (psychostimulant) with more pronounced effects on central than on motor activities. The mechanism of action in humans is not fully understood; however, it is thought that the effect is due to inhibition of dopamine reuptake in the striatum without triggering a release of dopamine. |
| List of Excipients |
|---|
|
Tablet content: Lactose monohydrate Tablet coating: Polyvinyl alcohol, part hydrolyzed Printing ink: Shellac glaze |
HDPE bottle with a child-resistant PP closure with silica gel desiccant integrated into the closure.
18 mg tablets: 28, 30 or 90 prolonged-release tablets.
Not all pack sizes may be marketed.
Accord-UK Ltd (Trading style: Accord), Whiddon Valley, Barnstaple, Devon, EX32 8NS
PL 0142/1220
15/11/2019
| Drug | Countries | |
|---|---|---|
| DELMOSART | New Zealand, Poland, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.